Literature DB >> 8151800

Discrepancy between infectivity and antigenicity stabilization of oral poliovirus vaccine by a capsid-binding compound.

K Andries1, B Rombaut, B Dewindt, A Boeyé.   

Abstract

Two hundred forty pyridazinamine derivatives were tested for the ability to stabilize the antigenicity and infectivity of oral poliovirus vaccine subjected to 45 degrees C for 2 h. Seven compounds stabilized the antigenicity of all three vaccine strains and neutralized the viral particles in a way that is reversible by dilution. Of these, R 77975 (pirodavir) was selected for vaccine potency tests. Sabin type 2 and type 3 strains were subjected to 4, 25, 42, and 45 degrees C for 1 week in the presence and absence of R 77975. Although R 77975 particularly stabilized the infectivity of the most thermolabile vaccine strain (Sabin type 3), the protection did not exceed that of 1 M MgCl2. When virus was inactivated in the absence of R 77975, the native or N antigenicity changed in H antigenicity. However, in the presence of the capsid-binding compound, N antigenicity was preserved in particles that had lost infectivity.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8151800      PMCID: PMC236833     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  15 in total

1.  REACTIVATION OF NEUTRALIZED VIRUS BY FLUOROCARBON: MECHANISM OF ACTION AND DEMONSTRATION OF REDUCED REACTIVABILITY WITH TIME OF VIRUS-ANTIBODY INTERACTION.

Authors:  S E SVEHAG
Journal:  Virology       Date:  1963-10       Impact factor: 3.616

2.  A comparison of WIN 51711 and R 78206 as stabilizers of poliovirus virions and procapsids.

Authors:  B Rombaut; K Andries; A Boeyé
Journal:  J Gen Virol       Date:  1991-09       Impact factor: 3.891

3.  Lack of quantitative correlation between inhibition of replication of rhinoviruses by an antiviral drug and their stabilization.

Authors:  K Andries; B Dewindt; J Snoeks; R Willebrords
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

4.  A simple quantitative protein A micro-immunoprecipitation method; assay of antibodies to the N and H antigens of poliovirus.

Authors:  R Vrijsen; B Rombaut; A Boeyé
Journal:  J Immunol Methods       Date:  1983-04-29       Impact factor: 2.303

5.  In vitro and in vivo activities of WIN 54954, a new broad-spectrum antipicornavirus drug.

Authors:  M G Woods; G D Diana; M C Rogge; M J Otto; F J Dutko; M A McKinlay
Journal:  Antimicrob Agents Chemother       Date:  1989-12       Impact factor: 5.191

6.  Direct and specific inactivation of rhinovirus by chalcone Ro 09-0410.

Authors:  H Ishitsuka; Y T Ninomiya; C Ohsawa; M Fujiu; Y Suhara
Journal:  Antimicrob Agents Chemother       Date:  1982-10       Impact factor: 5.191

7.  In vitro activity of pirodavir (R 77975), a substituted phenoxy-pyridazinamine with broad-spectrum antipicornaviral activity.

Authors:  K Andries; B Dewindt; J Snoeks; R Willebrords; K van Eemeren; R Stokbroekx; P A Janssen
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

8.  In vitro activity of WIN 51711, a new broad-spectrum antipicornavirus drug.

Authors:  M J Otto; M P Fox; M J Fancher; M F Kuhrt; G D Diana; M A McKinlay
Journal:  Antimicrob Agents Chemother       Date:  1985-06       Impact factor: 5.191

9.  Study of the parameters of binding of R 61837 to human rhinovirus 9 and immunobiochemical evidence of capsid-stabilizing activity of the compound.

Authors:  M Moeremans; M De Raeymaeker; G Daneels; M De Brabander; F Aerts; C Janssen; K Andries
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

10.  4',6-Dichloroflavan (BW683C), a new anti-rhinovirus compound.

Authors:  D J Bauer; J W Selway; J F Batchelor; M Tisdale; I C Caldwell; D A Young
Journal:  Nature       Date:  1981-07-23       Impact factor: 49.962

View more
  2 in total

1.  Thermal inactivation of oral polio vaccine: contribution of RNA and protein inactivation.

Authors:  B Rombaut; B Verheyden; K Andries; A Boeyé
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

2.  Potential use of antiviral agents in polio eradication.

Authors:  Armando M De Palma; Gerhard Pürstinger; Eva Wimmer; Amy K Patick; Koen Andries; Bart Rombaut; Erik De Clercq; Johan Neyts
Journal:  Emerg Infect Dis       Date:  2008-04       Impact factor: 6.883

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.